Structure of the human PKD1-PKD2 complex
Mutations in two genes, PKD1 and PKD2, account for most cases of autosomal dominant polycystic kidney disease, one of the most common monogenetic disorders. Here we report the 3.6-angstrom cryo–electron microscopy structure of truncated human PKD1-PKD2 complex assembled in a 1:3 ratio. PKD1 contains a voltage-gated ion channel (VGIC) fold that interacts with PKD2 to form the domain-swapped, yet noncanonical, transient receptor potential (TRP) channel architecture. The S6 helix in PKD1 is broken in the middle, with the extracellular half, S6a, resembling pore helix 1 in a typical TRP channel. Three positively charged,...
Source: ScienceNOW - September 6, 2018 Category: Science Authors: Su, Q., Hu, F., Ge, X., Lei, J., Yu, S., Wang, T., Zhou, Q., Mei, C., Shi, Y. Tags: Biochemistry, Online Only r-articles Source Type: news
Tolvaptan Works Long Term in Autosomal Dominant Polycystic Kidney Disease Tolvaptan Works Long Term in Autosomal Dominant Polycystic Kidney Disease
A new study demonstrates the long-term efficacy of the vasopressin-2 receptor antagonist tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Kidney disease treatment with roots in KC wins approval after 36 years
The Food and Drug Administration gave the green light for the first approved treatment for polycystic kidney disease on Tuesday — a treatment based on research that traces its roots to Kansas City.
In the 1960s, late nephrologist and University of Kansas Medical Center Researcher Dr. Jared Grantham discovered the kidney’s components during a research fellowship. Later on, he found a signaling molecule called cyclic AMP that affects the cell growth and fluid secretion in kidneys. This discovery… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2018 Category: Biotechnology Authors: Elise Reuter Source Type: news
Kidney disease treatment with roots in KC wins approval after 36 years
The Food and Drug Administration gave the green light for the first approved treatment for polycystic kidney disease on Tuesday — a treatment based on research that traces its roots to Kansas City.
In the 1960s, late nephrologist and University of Kansas Medical Center Researcher Dr. Jared Grantham discovered the kidney’s components during a research fellowship. Later on, he found a signaling molecule called cyclic AMP that affects the cell growth and fluid secretion in kidneys. This discovery… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2018 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 24, 2018 -- TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved Jynarque (tolvaptan) as the first drug treatment to slow kidney function decline in adults at... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 24, 2018 Category: Drugs & Pharmacology Source Type: news
Regulation of Cyst Growth in Polycystic Kidney Disease
Cilia, tiny hair-like structures on the kidney, and polycystin-1 and 2 genes, work together to promote cyst growth in mice with polycystic kidney disease. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news
Former Boston City Councilor John Nucci Waits For A New Kidney
BOSTON (CBS) – John Nucci, a former Boston City Councilor, has developed a genetic disorder and desperately needs a kidney.
Nucci is battling Polycystic Kidney Disease and is in the final stages of renal failure.
He joined Liam Martin and Paula Ebben on WBZ-TV to discuss Kidney Awareness Month and how to become a living a donor.
For more information visit: www.mghlivingdonors.org (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 1, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local John Nucci Kidney liam martin Paula Ebben Polycystic Kidney Disease Source Type: news
Trial to study water as treatment for polycystic kidney disease
Researchers in Australia are conducting a trial to determine whether a prescribed amount of water can reduce kidney failure. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 29, 2018 Category: Consumer Health News Source Type: news
Tolvaptan and Kidney Function Decline in ADPKD Patients Tolvaptan and Kidney Function Decline in ADPKD Patients
Dr Bansal reviews several studies on the effects of tolvaptan in patients with autosomal dominant polycystic kidney disease. What do the recent trials tell us?Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2017 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
NJ boy gets transplant after living without kidneys
Ismael Rodriguez-Reyes, 7, was born with polycystic kidney disease, which caused the kidneys to overgrow and form cysts. After finally getting new organs he hopes to return home to New Jersey. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2017 Category: Consumer Health News Source Type: news
Boy, 7, gets transplant after living without kidneys
Ismael Rodriguez-Reyes, 7, was born with polycystic kidney disease, which caused the kidneys to overgrow and form cysts. After finally getting new organs he hopes to return home to New Jersey. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2017 Category: Consumer Health News Source Type: news
New findings on tolvaptan as autosomal dominant polycystic kidney disease treatment
(Mayo Clinic) A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 4, 2017 Category: International Medicine & Public Health Source Type: news
Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment
ROCHESTER, Minn. ? A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. The results are published today in the New England Journal of Medicine. Autosomal dominant [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - November 4, 2017 Category: Hospital Management Source Type: news
Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 31, 2017 Category: Intensive Care Tags: Nephrology News Source Type: news
Green mamba venom could treat kidney disease
A peptide in green mamba venom can reduce the severity of a genetic disorder called polycystic kidney disease (PKD), researchers from France, Belgium and Germany have found. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2017 Category: Consumer Health News Source Type: news
